New Cohort and major partner for Tech4Eva Accelerator

Please login or
register
15.03.2023
Tech4Eva Opening Ceremony

Building on the success of its first two years, Tech4Eva, a unique international accelerator in Switzerland, has announced its new cohort at the 3rd edition kick-off organized in Kaiseraugst near Basel, in partnership with Roche. This year, Tech4Eva has attracted 147 projects from 40 countries, an increase of 18.5% with respect to the 2nd edition and 33.6% compared to the first. Interestingly 80% of the start-ups were once again created by women. Four Swiss startups are part of the new cohort.

For this third edition, a selection committee chose 21 start-ups from 147 applications from Switzerland and elsewhere in the world. 14 Swiss start-ups applied this year and four were selected by the jury.

The three most represented topics among start-ups offering innovative solutions in women's health are 1. Menstruation and sexual health: 22% of start-ups 2. Women's mental health and well-being: 18% of start-ups 3. Pregnancy and postpartum: 15% of start-ups. The solutions envisaged to respond to these challenges are numerous but focus on three major areas: 1. Mobile application: 18%. 2. Computer software: 16%. 3. Medical devices: 14%.

These figures clearly show that in women's health too, digitalisation is at the heart of the reflections. Moreover, two Swiss projects selected perfectly reflect this reality:

  • Adira Health is active in pregnancy and wellbeing. The startup empowers pregnant women suffering from high blood pressure, measuring their vitals, assessing their physical and mental wellbeing to provide real-time, data-informed guidance, through their blended maternity care pathway. Adira combines the power of AI with a personal perinatal coach to fight for healthy moms and stronger babies. 
  • HEALTHY-LONGER analyzes mental health symptoms together with the bio-chemical pathways of 21 essential neuro-biomarkers in dried urine probes for neuro-nutrient deficiencies. Based on this they provide their clients with personalized, effective and scientifically proven neuro-nutritional recommendations from foods available in most grocery shops. 

The two other Swiss startups joining the new cohort are:

  • WakeUp Pelvic is building a digital solution for pelvic physiotherapists and their patients.
  • Beyond Genomix is a clinical stage Swiss medtech developing next generation technologies for non-coding DNA analysis. With a focus on reproductive health, the startup has developed the only infertility test in the world, capable of explaining every infertility including that of idiopathic patients, male and female, from the comfort of their home. 

A fifth company is registered in Switzerland and has close ties to the country although activities are focused on Kenya

  • Malaica is designing a remote pregnancy support program to make pregnancy safe and
    convenient for African Pregnant women.

Selected International startups are: Care Mother; Egal Pads; Hale; Hyivy Health; Intignus Biotech; Luma Womb; Manina Medtech; MIM Solutions; Natal Cares; Neuraura; NuroKor Femtech; Predilife; Ru Medical; Samphire Neuroscience; The Palpa Co.; Selfcerve

Promising new partnership with Roche

Roche is collaborating for the first time with the Tech4Eva accelerator by hosting the launch event at its premises in Kaiseraugst near Basel. With this partnership, Tech4Eva expands further in the German- speaking part of Switzerland and can count on a major healthcare player in Switzerland. Roche has a long history in the field and has been strongly committed to women’s health and driving innovation to advance healthcare. In 2022, Roche launched its long-term initiative, XProject, which aims to identify and remove the most critical barriers so women can fully and equitably access healthcare. This connection between Roche's XProject and Tech4Eva, initiated by the EPFL Innovation Park and Groupe Mutuel, will create great synergies to support start-ups active in advancing women's health.

(Press release - ES)
Photo: Groupe Mutuel                   

0Comments

rss